Associated Papers
Type II kinase inhibitors that target Parkinson's disease-associated LRRK2.
Raig ND et al.
Science Advances, 2025
40465731 (PubMed )
Supplement: sciadv.adt2050_data_s1.zip › adt2050_data_s1.xlsx › Fig_4c
Phosphorylation determines the glucose metabolism reprogramming and tumor-promoting activity of sine oculis homeobox 1.
Lin Y et al.
Signal Transduction and Targeted Therapy, 2024
Targeting KRAS-mutant stomach/colorectal tumors by disrupting the ERK2-p53 complex.
Wang X et al.
Cell Reports, 2023
Sensitivity of Oncogenic KRAS-Expressing Cells to CDK9 Inhibition.
Lai LP et al.
Slas Discovery : Advancing Life Sciences R & D, 2021
Identification and Characterization of a B-Raf Kinase α-Helix Critical for the Activity of MEK Kinase in MAPK Signaling.
Nguyen D et al.
Biochemistry, 2020
Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.
Brenan L et al.
Cell Reports, 2016
Variants of the yeast MAPK Mpk1 are fully functional independently of activation loop phosphorylation.
Goshen-Lago T et al.
Molecular Biology of the Cell, 2016
Intrinsically active variants of Erk oncogenically transform cells and disclose unexpected autophosphorylation capability that is independent of TEY phosphorylation.
Smorodinsky-Atias K et al.
Molecular Biology of the Cell, 2016
ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.
Goetz EM et al.
Cancer Research, 2014
Copper is required for oncogenic BRAF signalling and tumorigenesis.
Brady DC et al.
Nature, 2014
Profiling the human protein-DNA interactome reveals ERK2 as a transcriptional repressor of interferon signaling.
Hu S et al.
Cell, 2009
Select a paper to view details